State of the art in immunotherapy of neuroblastoma.

Antibodies, Monoclonal / immunology Antineoplastic Agents / immunology Child Clinical Trials as Topic Gangliosides / antagonists & inhibitors Humans Immunotherapy / methods Molecular Targeted Therapy / methods N-Myc Proto-Oncogene Protein / genetics Neuroblastoma / genetics Treatment Outcome
cancer chimeric antibody receptor T cells immunotherapy monoclonal antibodies neuroblastoma

Journal

Immunotherapy
ISSN: 1750-7448
Titre abrégé: Immunotherapy
Pays: England
ID NLM: 101485158

Informations de publication

Date de publication:
06 2019
Historique:
pubmed: 17 5 2019
medline: 21 4 2020
entrez: 17 5 2019
Statut: ppublish

Résumé

Neuroblastoma (NB) is a common and deadly malignancy mostly observed in children. Evolution of therapeutic options for NB led to the addition of immunotherapeutic modalities to the previously recruited chemotherapeutic options. Molecular studies of the NB cells resulted in the discovery of many tumor-associated genes and antigens such as

Identifiants

DOI: 10.2217/imt-2019-0018 PMID: 31094257
pubmed: 31094257
doi: 10.2217/imt-2019-0018
doi:

Substances chimiques

Antibodies, Monoclonal 0
Antineoplastic Agents 0
Gangliosides 0
N-Myc Proto-Oncogene Protein 0
ganglioside, GD2 65988-71-8
dinutuximab 7SQY4ZUD30

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

831-850

Auteurs

Parnian Jabbari (P)

Research Center for Immunodeficiencies (RCID), Children's Medical Center, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Network of Immunity in Infection, Malignancy & Autoimmunity (NIIMA), Universal Scientific Education & Research Network (USERN), Tehran, Iran.

Sara Hanaei (S)

Research Center for Immunodeficiencies (RCID), Children's Medical Center, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Network of Immunity in Infection, Malignancy & Autoimmunity (NIIMA), Universal Scientific Education & Research Network (USERN), Tehran, Iran.

Nima Rezaei (N)

Research Center for Immunodeficiencies (RCID), Children's Medical Center, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Department of Immunology, School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Network of Immunity in Infection, Malignancy & Autoimmunity (NIIMA), Universal Scientific Education & Research Network (USERN), Tehran, Iran.
ORCID: 0000-0002-3836-1827

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › State of the art in immunotherapy of neuroblastoma.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › State of the art in immunotherapy of neuroblastoma.
questionsmedicales.fr › Personnes › Tranches d'âge › Enfant › State of the art in immunotherapy of neuroblastoma.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Essais cliniques comme sujet › State of the art in immunotherapy of neuroblastoma.
questionsmedicales.fr › Lipides › Lipides membranaires › Sphingolipides › Glycosphingolipides › Glycosphingolipides acides › Gangliosides › State of the art in immunotherapy of neuroblastoma.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › State of the art in immunotherapy of neuroblastoma.
questionsmedicales.fr › Thérapeutique › Biothérapie › Immunothérapie › State of the art in immunotherapy of neuroblastoma.
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Thérapie moléculaire ciblée › State of the art in immunotherapy of neuroblastoma.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Facteurs de transcription à motif basique et à glissière à leucines › Facteurs de transcription à motifs basiques hélice-boucle-hélice et à glissière à leucines › Protéine du proto-oncogène N-Myc › State of the art in immunotherapy of neuroblastoma.
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs du tissu nerveux › Tumeurs neuroectodermiques › Tumeurs neuroépitheliales › Tumeurs neuroectodermiques primitives › Tumeurs neuroectodermiques primitives périphériques › Neuroblastome › State of the art in immunotherapy of neuroblastoma.
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › State of the art in immunotherapy of neuroblastoma.